Capstone Therapeutics Corp. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. The company incurred a net loss attributable to the company stockholders in the second quarter of 2014 of $1.4 million or $0.03 per basic and diluted share compared to a net loss of $1.0 million or $0.02 per basic and diluted share in the second quarter of 2013. Net loss fluctuates primarily from the inclusion of the operating expenses of LipimetiX Development, LLC, which totaled (net of intercompany transactions) $987,000 for the three months ended June 30, 2014, and $584,000 for the three months ended June 30, 2013. Loss from continuing operations before taxes was $1,391,000 against $1,029,000 a year ago. Loss from continuing operations was $1,391,000 against $1,008,000 a year ago.

The company incurred a net loss attributable to the company stockholders in the six months ended June 30, 2014 of $2.4 million or $0.06 per basic and diluted share compared to a net loss of $2.0 million or $0.05 per basic and diluted share for the same period in 2013. Net Loss includes the operating expenses of LipimetiX Development, LLC, which totaled (net of intercompany transactions) $1,408,000 for the six months ended June 30, 2014, and $1,415,000 for the six months ended June 30, 2013. Loss from continuing operations before taxes was $2,413,000 against $2,218,000 a year ago. Loss from continuing operations was $2,413,000 against $2,197,000 a year ago.